U.S. patent application number 12/914045 was filed with the patent office on 2011-02-17 for azolopyridin-2-one derivatives as lipase and phospholipase inhibitors.
This patent application is currently assigned to SANOFI-AVENTIS. Invention is credited to Hubert Heuer, Gunter Muller, Stefan Petry, Norbert Tennagels, Gerhard Zoller.
Application Number | 20110039883 12/914045 |
Document ID | / |
Family ID | 37076291 |
Filed Date | 2011-02-17 |
United States Patent
Application |
20110039883 |
Kind Code |
A1 |
Zoller; Gerhard ; et
al. |
February 17, 2011 |
AZOLOPYRIDIN-2-ONE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE
INHIBITORS
Abstract
The present invention provides compounds which have an
inhibitory effect on hormone-sensitive lipase or endothelial
lipase. The compounds of the invention are azolopyridin-2-one
derivatives of the general formula I ##STR00001## wherein the
substituents are as defined herein. The compounds of formula I
wherein R2 is hydrogen are distinguished by favorable effects on
disorders of lipid metabolism. They beneficially influence the HDL
to LDL ratio and increase in particular the HDL level and are
suitable for the prevention and treatment of dyslipidemias and
metabolic syndrome and their diverse sequelae such as
atherosclerosis, coronary heart disease, heart failure, obesity and
diabetes. The compounds of formula I wherein R1 and R2 together
form a ring system are distinguished by favorable effects on
metabolic disorders. They beneficially influence lipid and sugar
metabolism; in particular they lower the triglyceride level and are
suitable for the prevention and treatment of type II diabetes and
arteriosclerosis and the diverse sequelae thereof.
Inventors: |
Zoller; Gerhard; (Frankfurt
am Main, DE) ; Petry; Stefan; (Frankfurt am Main,
DE) ; Muller; Gunter; (Frankfurt am Main, DE)
; Heuer; Hubert; (Frankfurt am Main, DE) ;
Tennagels; Norbert; (Frankfurt am Main, DE) |
Correspondence
Address: |
Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City
NY
11530
US
|
Assignee: |
SANOFI-AVENTIS
Paris
FR
|
Family ID: |
37076291 |
Appl. No.: |
12/914045 |
Filed: |
October 28, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11950932 |
Dec 5, 2007 |
7846943 |
|
|
12914045 |
|
|
|
|
PCT/EP2006/005095 |
May 27, 2006 |
|
|
|
11950932 |
|
|
|
|
Current U.S.
Class: |
514/302 ;
546/116 |
Current CPC
Class: |
A61P 43/00 20180101;
A61P 9/10 20180101; C07D 498/04 20130101; A61P 3/06 20180101; A61P
3/00 20180101; A61P 3/10 20180101; A61P 5/50 20180101; A61P 9/00
20180101 |
Class at
Publication: |
514/302 ;
546/116 |
International
Class: |
A61K 31/437 20060101
A61K031/437; A61P 5/50 20060101 A61P005/50; A61P 3/10 20060101
A61P003/10; A61P 3/06 20060101 A61P003/06; A61P 9/10 20060101
A61P009/10; C07D 498/04 20060101 C07D498/04 |
Foreign Application Data
Date |
Code |
Application Number |
Jun 9, 2005 |
DE |
102005026762.9 |
Claims
1-15. (canceled)
16. A method for the treatment or prevention of insulin resistance
in a patient, which comprises administering to said patient a
therapeutically effective amount of a compound of formula I
##STR00005## wherein: is independently selected from .dbd.C(--R)--
and .dbd.N--, with the proviso that at least one and at most two of
X is .dbd.N--; Y is --O-- or --S--; R is independently selected
from hydrogen, halogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.1-C.sub.3alkyloxy-(C.sub.1-C.sub.3)-alkylene, hydroxy,
(C.sub.1-C.sub.6)-alkylmercapto, amino, (C.sub.1-C.sub.6E
alkylamino, di-(C.sub.7-C.sub.12)-alkylamino,
(C.sub.1-C.sub.6)-alkylcarbonyl, COOR3, trifluoromethyl,
(C.sub.1-C.sub.6)-alkylsulfonyl, aminosulfonyl,
pentafluorosulfanyl, (C.sub.6-C.sub.10)-aryl,
(C.sub.5-C.sub.12)-heteroaryl, CO--NR6R7, O--CO--NR6R7,
O--CO--(C.sub.1-C.sub.6)-alkylene-CO--O--(C.sub.1-C.sub.6)-alkyl,
O--CO--(C.sub.1-C.sub.6)-alkylene-CO--OH,
O--CO--(C.sub.1-C.sub.6)-alkylene-CO--NR6R7 and unsubstituted or
mono- or poly-F-substituted (C.sub.1-C.sub.6)-alkyloxy; R1 is
selected from (C.sub.4-C.sub.16)-alkyl,
(C.sub.1-C.sub.4)-alkylene-(C.sub.6-C.sub.10)-aryl,
(C.sub.1-C.sub.4) alkylene-(C.sub.5-C.sub.12)-heteroaryl,
(C.sub.1-C.sub.4)-alkylene-(C.sub.3-C.sub.12)-cycloalkyl, and
(C.sub.8-C.sub.14)-bicycle, wherein each of said aryl, heteroaryl,
cycloalkyl and bicycle may be substituted one or more times by a
substituent selected from halogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.1-C.sub.3)-alkyloxy, hydroxy,
(C.sub.1-C.sub.6)-alkylmercapto, amino,
(C.sub.1-C.sub.6)-alkylamino, di-(C.sub.2-C.sub.12)-alkylamino,
mono-(C.sub.1-C.sub.6)-alkylaminocarbonyl,
di-(C.sub.2-C.sub.8)-alklaminocarbonyl,
(C.sub.1-C.sub.6)-alkoxycarbonyl, (C.sub.1-C.sub.6)-alkylcarbonyl,
cyano, trifluoromethyl, trifluoromethyloxy,
(C.sub.1-C.sub.6)-alkylsulfonyl, and aminosulfonyl; R2 is selected
from hydrogen and (C.sub.1-C.sub.6)-alkyl; or, in the alternative,
R1 and R2 form, together with the nitrogen atom to which they are
attached, a monocyclic, saturated or partially unsaturated 4- to
7-membered ring system or a bicyclic saturated or partially
unsaturated 8- to 14-membered ring system, of which individual
members of the ring systems may be replaced by one to three atoms
or atomic groups selected from --CHR4-, --CR4R5-, --(C.dbd.R4)-,
--C(.dbd.O)--, --O--, --S--, --SO--, --SO.sub.2--, with the proviso
that no two of the units --O--, --S--, --SO--, and --SO.sub.2-- may
be adjacent to each other; R3 is hydrogen, (C.sub.1-C.sub.6)-alkyl,
or benzyl; R4 and R5 are independently selected from
(C.sub.1-C.sub.6)-alkyl, halogen, trifluoromethyl, COOR3,
cyclopropyl, and cyclopropylene; and R6 and R7 are independently
selected from hydrogen, (C.sub.1-C.sub.6)-alkyl,
--(C.sub.6-C.sub.10)-aryl, (C.sub.5-C.sub.12)-heteroaryl,
(C.sub.3-C.sub.12)-cycloalkyl,
(C.sub.1-C.sub.4)-alkylene-(C.sub.6-C.sub.10)-aryl,
(C.sub.1-C.sub.4)-alkylene-(C.sub.5-C.sub.12)-heteroaryl,
(C.sub.1-C.sub.4)-alkylene-(C.sub.4-C.sub.12)-cycloalkyl, and
(C.sub.8-C.sub.14)-bicycle; or a pharmaceutically acceptable salt
thereof.
17. A method for the treatment or prevention of diabetes mellitus
and the sequelae associated therewith in a patient, which comprises
administering to said patient a therapeutically effective amount of
a compound of formula I as claimed in claim 16 or a
pharmaceutically acceptable salt thereof.
18. A method for the treatment or prevention of dyslipidemias and
the sequelae thereof in a patient, which comprises administering to
said patient a therapeutically effective amount of a compound of
formula I as claimed in claim 16 or a pharmaceutically acceptable
salt thereof.
19. A method for the treatment or prevention of conditions
associated with metabolic syndrome in a patient, which comprises
administering to said patient a therapeutically effective amount of
a compound of formula I as claimed in claim 16 or a
pharmaceutically acceptable salt thereof.
20. A method for the treatment or prevention of conditions
associated with reduced HDL level in a patient, which comprises
administering to said patient a therapeutically effective amount of
a compound of formula I as claimed in claim 16 or a
pharmaceutically acceptable salt thereof.
21. A method for the treatment or prevention of atherosclerotic
disorders in a patient, which comprises administering to said
patient a therapeutically effective amount of a compound of formula
I as claimed in claim 16 or a pharmaceutically acceptable salt
thereof
22. A process for preparing a compound of formula I as claimed in
claim 16, which comprises: acylating an azolopyridin-2-one
derivative of formula II with a carbamoyl chloride of formula III;
or in two stages, reacting said azolopyridin-2-one derivative of
formula II first with phosgene or a phosgene equivalent chosen from
trichloromethyl chlorocarbonate, ditrichloromethyl carbonate or
4-nitrophenyl chloroformate, and, in a second step, reacting the
resulting intermediate with an amine of formula IV, in which the
substituents are as defined in claim 16. ##STR00006##
23. A process for preparing a compound of formula I as claimed in
claim 16, wherein R2 is hydrogen, which comprises reacting an
azolopyridin-2-one derivative of formula II with an isocyanate of
formula V: O.dbd.C.dbd.N--R1. ##STR00007##
Description
[0001] This application is a continuation of International
application No. PCT/EP2006/005,095, filed May 27, 2006, which is
incorporated herein by reference in its entirety; which claims the
benefit of priority of German Patent Application No. 10 2005 026
762.9, filed Jun. 9, 2005.
[0002] The present invention relates to azolopyridin-2-one
derivatives of the general formula I, to their pharmaceutically
useful salts and to their use as medicinal substances.
[0003] Compounds of similar structure are known from EP 1275653.
However, these are used as fungicides.
[0004] Compounds having an inhibitory effect on hormone-sensitive
lipase are described in the prior art for example in WO2004/035550,
WO2005/073199 or WO03/051842.
[0005] Compounds with an inhibitory effect on endothelial lipase
are described in the prior art for example in WO2004/094394,
WO2004/094393.
[0006] The present invention provides compounds which have an
inhibitory effect on hormone-sensitive lipase or endothelial
lipase.
[0007] The invention relates to azolopyridin-2-one derivatives of
the general formula I
##STR00002##
in which the meanings are: [0008] X identically or differently
.dbd.C(--R)-- or .dbd.N--, where at least one and at most two
.dbd.C(--R--)-- is replaced by .dbd.N--; [0009] Y --O-- or --S--;
[0010] R identically or differently hydrogen, halogen,
(C.sub.1-C.sub.6)-alkyl,
(C.sub.1-C.sub.3)-alkyloxy-(C.sub.1-C.sub.3)-alkylene, hydroxy,
(C.sub.1-C.sub.6)-alkylmercapto, amino,
(C.sub.1-C.sub.6)-alkylamino, di-(C.sub.2-C.sub.12)-alkylamino,
(C.sub.1-C.sub.6)-alkylcarbonyl, COOR3, trifluoromethyl,
(C.sub.1-C.sub.6)-alkylsulfonyl, (C.sub.1-C.sub.6)-alkylsulfinyl,
aminosulfonyl, pentafluorosulfanyl, (C.sub.6-C.sub.10)-aryl,
(C.sub.6-C.sub.12)-heteroaryl, CO--NR6R7, O--CO--NR6R7,
O--CO--(C.sub.1-C.sub.6)-alkylene-CO--O--(C.sub.1-C.sub.6)-alkyl,
O--CO --(C.sub.1-C.sub.6)-alkylene-CO--OH,
O--CO--(C.sub.1-C.sub.6)-alkylene-CO--NR6R7 or unsubstituted or
mono- or poly-F-substituted (C.sub.1-C.sub.6)-alkyloxy; [0011] R1
is (C.sub.4-C.sub.16)-alkyl,
(C.sub.1-C.sub.4)-alkylene-(C.sub.6-C.sub.10)-aryl,
(C.sub.1-C.sub.4)-alkylene-(C.sub.5-C.sub.12)-heteroaryl,
(C.sub.1-C.sub.4)-alkylene-(C.sub.3-C.sub.12)-cycloalkyl,
(C.sub.8-C.sub.14)-bicycle, where aryl, heteroaryl, cycloalkyl or
bicycle may be substituted one or more times by halogen,
(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.3)-alkyloxy, hydroxy,
(C.sub.1-C.sub.6)-alkylmercapto, amino,
(C.sub.1-C.sub.6)-alkylamino, di-(C.sub.2-C.sub.12)-alkylamino,
mono-(C.sub.1-C.sub.6)-alkylaminocarbonyl,
di-(C.sub.2-C.sub.8)-alkylaminocarbonyl,
(C.sub.1-C.sub.6)-alkoxycarbonyl, (C.sub.1-C.sub.6)-alkylcarbonyl,
cyano, trifluoromethyl, trifluoromethyloxy,
(C.sub.1-C.sub.6)-alkylsulfonyl, aminosulfonyl; [0012] R2 is
hydrogen, (C.sub.1-C.sub.6)-alkyl; or [0013] R1 and R2 form
together with the nitrogen atom bearing them a monocyclic,
saturated or partially unsaturated 4- to 7-membered ring system or
a bicyclic saturated or partially unsaturated 8- to 14-membered
ring system, of which individual members of the ring systems may be
replaced by one to three atoms or atomic groups from the series
--CHR4-, --CR4R5-, --(C.dbd.R4)-, --NR6-, --C(.dbd.O)--, --O--,
--S--, --SO--, --SO.sub.2--, with the proviso that two units from
the series --O--, --S--, --SO--, --SO.sub.2-- may not be adjacent;
[0014] R3 hydrogen, (C.sub.1-C.sub.6)-alkyl, benzyl; [0015] R4, R5
identically or differently (C.sub.1-C.sub.6)-alkyl, halogen,
trifluoromethyl, COOR3, cyclopropyl, cyclopropylene; [0016] R6, R7
identically or differently hydrogen, (C.sub.1-C.sub.6)-alkyl,
--(C.sub.6-C.sub.10)-aryl, (C.sub.5-C.sub.12)-heteroaryl,
(C.sub.3-C.sub.12)-cycloalkyl,
(C.sub.1-C.sub.4)-alkylene-(C.sub.6-C.sub.10)-aryl,
(C.sub.1-C.sub.4)-alkylene-(C.sub.5-C.sub.12)-heteroaryl,
(C.sub.1-C.sub.4)-alkylene-(C.sub.4-C.sub.12)-cycloalkyl,
(C.sub.8-C.sub.14)-bicycle; the tautomeric forms of the compounds
and the physiologically tolerated salts thereof.
[0017] Preferred compounds of the formula I are those in which
[0018] R1 is (C.sub.5-C.sub.16)-alkyl,
(C.sub.1-C.sub.4)-alkylene-(C.sub.6-C.sub.10)-aryl,
(C.sub.1-C.sub.4)-alkylene-(C.sub.5-C.sub.12)-heteroaryl,
(C.sub.1-C.sub.4)-alkylene-(C.sub.3-C.sub.12)-cycloalkyl,
(C.sub.8-C.sub.14)-bicycle, where aryl, heteroaryl, cycloalkyl or
bicycle may be substituted one or more times by halogen,
(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.3)-alkyloxy, hydroxy,
(C.sub.1-C.sub.6)-alkylmercapto, amino,
(C.sub.1-C.sub.6)-alkylamino, di-(C.sub.2-C.sub.12-alkylamino,
mono-(C.sub.1-C.sub.6)-alkylaminocarbonyl,
di-(C.sub.2-C.sub.8)-alkylaminocarbonyl,
(C.sub.1-C.sub.6)-alkoxycarbonyl, (C.sub.1-C.sub.6)-alkylcarbonyl,
cyano, trifluoromethyl, trifluoromethyloxy,
(C.sub.1-C.sub.6)-alkylsulfonyl, aminosulfonyl.
[0019] Particularly preferred compounds of the formula I are those
in which [0020] X is identically or differently .dbd.C(--R)-- or
.dbd.N--, where one .dbd.C(--R--)-- is replaced by .dbd.N--; [0021]
Y is --O--, --S--; [0022] R is identically or differently hydrogen,
halogen, (C.sub.1-C.sub.6)-alkyl, hydroxy, trifluoromethyl,
mono-(C.sub.1-C.sub.6)-alkylaminocarbonyl,
di-(C.sub.2-C.sub.8)-alkylaminocarbonyl, COOR3,
(C.sub.1-C.sub.6)-alkylsulfonyl, aminosulfonyl,
(C.sub.6-C.sub.10)-aryl, (C.sub.5-C.sub.12)-heteroaryl,
(C.sub.1-C.sub.6)-alkylcarbonyl, CO--NR6R7, O--CO--NR6R7,
O--CO--(C.sub.1-C.sub.6)-alkylene-CO--O--(C.sub.1-C.sub.6)-alkyl,
O--CO--(C.sub.1-C.sub.6)-alkylene-CO--NR6R7 or unsubstituted or
mono- or poly-F-substituted (C.sub.1-C.sub.6)-alkyloxy; [0023] R1
is (C.sub.6-C.sub.12)-alkyl,
(C.sub.1-C.sub.3)-alkylene-(C.sub.6-C.sub.10)-aryl,
(C.sub.1-C.sub.3)-alkylene-(C.sub.5-C.sub.12)-heteroaryl,
(C.sub.1-C.sub.3)-alkylene-(C.sub.4-C.sub.12)-cycloalkyl,
(C.sub.8-C.sub.14)-bicycle, where aryl, heteroaryl, cycloalkyl or
bicycle may be substituted one or more times by halogen,
(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.3)-alkyloxy, hydroxy,
amino, (C.sub.1-C.sub.6)-alkylamino, trifluoromethyl; [0024] R2 is
hydrogen, (C.sub.1-C.sub.6)-alkyl; or [0025] R1 and R2 together
with the nitrogen atom bearing them are a monocyclic, saturated
5-to 6-membered ring system or a bicyclic saturated or partially
unsaturated 9-to 10 membered ring system, of which individual
members of the ring systems may be replaced by one to three atoms
or atomic groups from the series --CHR4-, --CR4R5-, --(C.dbd.R4)-,
--NR6-, --O--, --S--, with the proviso that two units from the
series --O--, --S-- may not be adjacent; [0026] R3 is hydrogen,
(C.sub.1-C.sub.6)-alkyl, benzyl; [0027] R4, R5 are identically or
differently (C.sub.1-C.sub.6)-alkyl, halogen, trifluoromethyl,
COOR3, cyclopropyl, cyclopropylene; [0028] R6, R7 are identically
or differently hydrogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.6-C.sub.10)-aryl, (C.sub.5-C.sub.12)-heteroaryl,
(C.sub.3-C.sub.12)-cycloalkyl,
(C.sub.1-C.sub.4)-alkylene-(C.sub.6-C.sub.10)-aryl,
(C.sub.1-C.sub.4)-alkylene-(C.sub.5-C.sub.12)-heteroaryl,
(C.sub.1-C.sub.4)-alkylene-(C.sub.4-C.sub.12)-cycloalkyl,
(C.sub.6-C.sub.14)-bicycle.
[0029] Particularly preferred compounds of the formula I are also
those in which [0030] X is identically or differently .dbd.C(--R)--
or .dbd.N--, where at least one .dbd.C(--R--)-- is replaced by
.dbd.N; [0031] Y is --O-- or --S--; [0032] R is identically or
differently hydrogen, halogen, (C.sub.1-C.sub.6)-alkyl, hydroxy,
trifluoromethyl, mono-(C.sub.1-C.sub.6)-alkylaminocarbonyl,
di-(C.sub.2-C.sub.8)-aryl, (C.sub.5-C.sub.12)-heteroaryl,
(C.sub.1-C.sub.6)-alkylcarbonyl, CO--NR6R7, O--CO--NR6R7,
O--CO--(C.sub.1-C.sub.6)-alkylene-CO--O--(C.sub.1-C.sub.6)-alkyl,
O--CO--(C.sub.1-C.sub.6)-alkylene-CO--NR6R7 or unsubstituted or
mono- or poly-F-substituted (C.sub.1-C.sub.6)-alkyloxy; [0033] R1
is (C.sub.6-C.sub.12)-alkyl,
(C.sub.1-C.sub.2)-alkylene-(C.sub.6-C.sub.10)-aryl,
(C.sub.1-C.sub.2)-alkylene-(C.sub.5-C.sub.12)-heteroaryl,
(C.sub.1-C.sub.2)-alkylene-(C.sub.4-C.sub.12)-cycloalkyl,
(C.sub.8-C.sub.14)-bicycle, where aryl, heteroaryl, cycloalkyl or
bicycle may be substituted one or more times by halogen,
(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.3)-alkyloxy, hydroxy,
amino, (C.sub.1-C.sub.6)-alkylamino, trifluoromethyl; [0034] R2 is
hydrogen; or [0035] R1 and R2 together with the nitrogen atom
bearing them are a monocyclic, saturated 5-to 6-membered ring
system or a bicyclic saturated or partially unsaturated 9-to 10
membered ring system, of which individual members of the ring
systems may be replaced by one to three atoms or atomic groups from
the series --CHR4-, --CR4R5-, --(C.dbd.R4)-, --NR6-, --O--, --S--,
with the proviso that two units from the series --O--, --S-- may
not be adjacent; [0036] R3 is hydrogen, (C.sub.1-C.sub.6)-alkyl,
benzyl; [0037] R4, R5 are identically or differently
(C.sub.1-C.sub.6)-alkyl, halogen, trifluoromethyl, COOR3,
cyclopropyl, cyclopropylene; [0038] R6, R7 are identically or
differently hydrogen, (C.sub.1-C.sub.6)-alkyl,
--(C.sub.6-C.sub.10)-aryl, (C.sub.3-C.sub.12)-cycloalkyl,
(C.sub.1-C.sub.4)-alkylene-(C.sub.6-C.sub.10)-aryl.
[0039] In a further particularly preferred embodiment of the
compounds of the formula I, [0040] R6, R7 are identically or
differently hydrogen, (C.sub.1-C.sub.6)-alkyl or
(C.sub.3-C.sub.6)-cycloalkyl.
[0041] Preferred compounds of the formula I are also those in which
[0042] X in position 5, 6 and 7 is identically or differently
.dbd.C(--R)--, in position 4 is .dbd.N--.
[0043] Further preferred compounds of the formula I are those in
which [0044] X where appropriate in position 4 or 7 is
.dbd.C(--R)-- with R=hydrogen, in position 5 or 6 is .dbd.C(--R)--
with R not hydrogen.
[0045] Very particularly preferred compounds of the formula I are
those in which [0046] Y is --O--, --S--; [0047] R1 is
(C.sub.6-C.sub.12)-alkyl, benzyl,
(C.sub.1-C.sub.3)-alkylene-(C.sub.5-C.sub.12)-heteroaryl,
(C.sub.1-C.sub.3)-alkylene-(C.sub.4-C.sub.12)-cycloalkyl,
(C.sub.8-C.sub.14)-bicycle, where benzyl, heteroaryl, cycloalkyl or
bicycle may be substituted by halogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.1-C.sub.3)-alkyloxy or trifluoromethyl; [0048] R2 is
hydrogen; or [0049] R1 and R2 together with the nitrogen atom
bearing them form a monocyclic, saturated 5- to 6-membered ring
system, of which individual members of the ring systems may be
replaced by one to two atoms or atomic groups from the series
--CHR4-, --NR6-, in which R4 is as defined above, and R6 is
(C.sub.1-C.sub.6)-alkyl or cyclopropyl.
[0050] In one embodiment of the compounds of the formula I, [0051]
X is identically or differently .dbd.C(--R)-- or .dbd.N--, where
one .dbd.C(--R--)-- is replaced by .dbd.N--;
[0052] In one embodiment of the compounds of the formula I, [0053]
Y is --O--.
[0054] In another embodiment of the compounds of the formula I,
[0055] Y is --S--.
[0056] In a particular embodiment of the compounds of the formula
I, [0057] R2 is hydrogen.
[0058] Further very particularly preferred compounds of the formula
I are those in which [0059] Y is --O--; [0060] R is identically or
differently hydrogen, halogen, hydroxy or (C.sub.1-C.sub.6)-alkyl;
[0061] R1 is (C.sub.7-C.sub.12)-alkyl, benzyl,
(C.sub.1-C.sub.3)-alkylene-(C.sub.5-C.sub.12)-heteroaryl,
(C.sub.1-C.sub.3)-alkylene-(C.sub.4-C.sub.12)-cycloalkyl,
(C.sub.8-C.sub.14)-bicycle, where benzyl, heteroaryl, cycloalkyl or
bicycle may be substituted by halogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.1-C.sub.3)-alkoxy or trifluoromethyl; [0062] R2 is
hydrogen.
[0063] Further very particularly preferred compounds of the formula
I are also those in which [0064] Y is --O--; [0065] R is
identically or differently hydrogen, halogen or
(C.sub.1-C.sub.6)-alkyl; [0066] R1 is (C.sub.6-C.sub.12)-alkyl,
benzyl, --CH.sub.2--(C.sub.5-C.sub.12)-heteroaryl,
--CH.sub.2--(C.sub.4-C.sub.12)-cycloalkyl,
(C.sub.8-C.sub.14)-bicycle, where benzyl, heteroaryl, cycloalkyl or
bicycle may be substituted by halogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.1-C.sub.3)-alkoxy or trifluoromethyl; [0067] R2 is
hydrogen.
[0068] Further very particularly preferred compounds of the formula
I are also those in which [0069] Y is --O--; [0070] R is
identically or differently hydrogen, halogen or
(C.sub.1-C.sub.6)-alkyl; [0071] R1 is (C.sub.6-C.sub.12)-alkyl,
benzyl, --CH.sub.2--(C.sub.4-C.sub.12)-cyclohexyl, indanyl,
tetrahydronaphthyl, where benzyl, cyclohexyl, indanyl or
tetrahydronaphthyl may be substituted by (C.sub.1-C.sub.6)-alkyl;
[0072] R2 is hydrogen.
[0073] The invention relates to compounds of the formula I in the
form of their salts, racemates, racemic mixtures and pure
enantiomers, and to their diastereomers and mixtures thereof.
[0074] The alkyl and alkylene radicals in the substituents R, R1,
R2, R3, R4, R5, R6 and R7 may be either straight-chain or branched.
Halogen is fluorine, chlorine, bromine or iodine, in particular
fluorine or chlorine. The alkyl and alkylene radicals may be
substituted one or more times by suitable groups
[0075] Aryl means an aromatic carbocyclic mono- or bicyclic ring
system which comprises 6 to 10 atoms in the ring or in the
rings.
[0076] The aryl radicals may be substituted one or more times by
suitable groups.
[0077] Heteroaryl is a mono- or bicyclic aromatic ring system
having 5 to 12 ring members, in which at least one atom in the ring
system is a heteroatom from the series N, O and S.
[0078] Suitable "heteroaryl rings" or "heteroaryl radicals" are,
for example, benzimidazolyl, benzofuranyl, benzothiophenyl,
benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl,
benzisoxazolyl, benzisothiazolyl, quinolinyl, furyl, furazanyl,
imidazolyl, 1H-indazolyl, indolyl, 1,2,3-oxadiazolyl,
1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl,
pyrimidinyl, pyrazinyl, pyrazolyl, pyridyl, pyrrolyl, thiazolyl,
1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl,
1,3,4-thiadiazolyl, thiophenyl.
[0079] Preferred heteroaryl radicals are thiophenyl, pyrazolyl and
pyridyl. The heteroaryl rings or heteroaryl radicals may be
substituted one or more times by suitable groups.
[0080] A cycloalkyl radical is a ring system which comprises one or
more rings and which is in saturated or partially unsaturated (with
one or two double bonds) form and which is composed exclusively of
carbon atoms.
[0081] The cycloalkyl radicals may be substituted one or more times
by suitable groups.
[0082] Bicycle means bicyclic ring systems which are in saturated
or partially unsaturated form and which, apart from carbon, may
also comprise one or more heteroatoms such as, for example,
nitrogen, oxygen or sulfur. This definition also includes ring
systems which comprise a fused benzene nucleus. Examples which may
be mentioned are the tetrahydronaphthyl, alpha- or beta-tetralon-,
indanyl- or indan-1-on-yl radical. Preferred bicyclic radicals are
those of formula Ic
##STR00003##
with q=1 or 2. The bicyclic radicals may be substituted one or more
times by suitable groups.
[0083] Pharmaceutically acceptable salts are, because their
solubility in water is greater than that of the initial or basic
compounds, particularly suitable for medical applications. These
salts must have a pharmaceutically acceptable anion or cation.
Suitable pharmaceutically acceptable acid addition salts of the
compounds of the invention are salts of inorganic acids such as
hydrochloric acid, hydrobromic, phosphoric, metaphosphoric, nitric
and sulfuric acid, and of organic acids such as, for example,
acetic acid, benzenesulfonic, benzoic, citric, ethanesulfonic,
fumaric, gluconic, glycolic, isethionic, lactic, lactobionic,
maleic, malic, methanesulfonic, succinic, p-toluenesulfonic and
tartaric acid. Suitable pharmaceutically acceptable basic salts are
ammonium salts, alkali metal salts (such as sodium and potassium
salts) and alkaline earth metal salts (such as magnesium and
calcium salts) and salts of trometamol
(2-amino-2-hydroxymethyl-1,3-propanediol), diethanolamine, lysine
or ethylenediamine.
[0084] Salts with a pharmaceutically unacceptable anion such as,
for example, trifluoroacetate likewise belong within the framework
of the invention as useful intermediates for the preparation or
purification of pharmaceutically acceptable salts and/or for use in
nontherapeutic, for example in vitro, applications.
[0085] The term "physiologically functional derivative" used herein
refers to any physiologically tolerated derivative of a compound of
the invention of the formula I, for example an ester, which on
administration to a mammal such as, for example, a human is able to
form (directly or indirectly) a compound of the formula I or an
active metabolite thereof.
[0086] Physiologically functional derivatives also include prodrugs
of the compounds of the invention as, for example, described in H.
Okada et al., Chem. Pharm. Bull. 1994, 42, 57-61. Such prodrugs can
be metabolized in vivo to a compound of the invention. These
prodrugs may themselves be active or not.
[0087] The compounds of the invention may also exist in various
polymorphous forms, for example as amorphous and crystalline
polymorphous forms. All polymorphous forms of the compounds of the
invention belong within the framework of the invention and are a
further aspect of the invention.
[0088] All references to "compound(s) of formula I" hereinafter
refer to compound(s) of the formula I as described above, and their
salts, solvates and physiologically functional derivatives as
described herein.
Use
[0089] The compounds of the invention of the general formula I have
a surprising inhibitory effect on hormone sensitive lipase, HSL, an
allosteric enzyme in adipocytes which is inhibited by insulin and
is responsible for the breakdown of fats in fat cells and thus for
transferring fat constituents into the blood stream. Inhibition of
this enzyme is therefore equivalent to an insulin-like effect of
the compounds of the invention, eventually leading to a reduction
of free fatty acids in the blood and of blood glucose. They can
therefore be employed for metabolic derangements such as, for
example, for non-insulin-dependent diabetes mellitus, for diabetic
syndrome and for direct pancreatic damage. The compounds of the
invention of the general formula I, especially those in which R2 is
hydrogen, may additionally have an inhibitory effect on endothelial
lipase (EL). The preferred substrate for EL is HDL, which has
antiatherosclerotic activity. A reduction in the HDL level leads to
progression of atherosclerosis and its sequelae such as coronary
heart disease and moreover favors development of the metabolic
syndrome and its sequelae diabetes. An inhibition of EL should thus
generally lead to prevention of atherosclerotic disorders and
indirectly reduce the probability of people with an increased risk
for diabetes becoming ill.
[0090] It has further been found that the inhibitory effect of the
compounds of the invention of the general formula I is selective in
relation to other lipases.
[0091] The compounds of the invention of the formula I may also
have an inhibitory effect on triglyceride lipase.
[0092] Compounds of this type are particularly suitable for the
treatment and/or prevention of [0093] 1.--Disorders of fatty acid
metabolism and glucose utilization disorders [0094] 2.--Disorders
of the insulin sensitivity of myo-, adipo- and hepatocytes (insulin
resistance)--metabolic syndrome [0095] 3. Diabetes mellitus,
especially type 2 diabetes, including the prevention of the
sequelae associated therewith.
[0096] Particular aspects in this connection are [0097]
hyperglycemia, [0098] improvement in insulin resistance, [0099]
improvement in glucose tolerance, [0100] protection of the
pancreatic .beta. cells [0101] prevention of macro- and
microvascular disorders [0102] 4. Dyslipidemias and the sequelae
thereof such as, for example, atherosclerosis, coronary heart
disease, cerebrovascular disorders etc., especially those (but not
restricted thereto) which are characterized by one or more of the
following factors: [0103] high plasma triglyceride concentrations,
high postprandial plasma triglyceride concentrations [0104] low HDL
cholesterol concentration [0105] low apoA lipoprotein
concentrations [0106] high LDL cholesterol concentrations [0107]
small dense LDL cholesterol particles [0108] high apoB lipoprotein
concentrations [0109] 5. Various other conditions which may be
associated with the metabolic syndrome, such as: [0110] obesity
(excess weight), including central obesity [0111] thromboses,
hypercoagulable and prothrombotic stages (arterial and venous)
[0112] high blood pressure [0113] heart failure such as, for
example (but not restricted thereto), following myocardial
infarction, hypertensive heart disease or cardiomyopathy [0114] 6.
Other disorders or conditions in which inflammatory reactions or
cell differentiation may for example be involved are: [0115]
atherosclerosis such as, for example (but not restricted thereto),
coronary sclerosis including angina pectoris or myocardial
infarction, stroke [0116] vascular restenosis or reocclusion [0117]
chronic inflammatory bowel diseases such as, for example, Crohn's
disease and ulcerative colitis [0118] pancreatitis [0119] other
inflammatory states [0120] retinopathy [0121] adipose cell tumors
[0122] adipose cell carcinomas such as, for example, liposarcoma
[0123] solid tumors and neoplasms such as, for example (but not
restricted thereto), carcinomas of the gastrointestinal tract, of
the liver, of the biliary tract and of the pancreas, endocrine
tumors, carcinomas of the lungs, of the kidneys and of the urinary
tract, of the genital tract, prostate carcinomas etc. acute and
chronic myeloproliferative disorders and lymphomas angiogenesis
[0124] neurodegenerative disorders [0125] Alzheimer's disease
[0126] multiple sclerosis [0127] Parkinson's disease
erythemato-squamous dermatoses such as, for example, psoriasis
[0128] acne vulgaris [0129] other skin disorders and dermatological
conditions which are modulated by PPAR [0130] eczemas and
neurodermatitis dermatitis such as, for example, seborrheic
dermatitis or photodermatitis [0131] keratitis and keratosis such
as, for example, seborrheic keratoses, senile keratoses, actinic
keratosis, photo-induced keratoses or keratosis follicularis [0132]
keloids and keloid prophylaxis [0133] warts, including condylomata
or condylomata acuminata [0134] human papilloma viral (HPV)
infections, such as, for example, venereal papillomata, viral warts
such as, for example, molluscum contagiosum, leukoplakia [0135]
papular dermatoses such as, for example, lichen planus [0136] skin
cancer such as, for example, basal cell carcinoma, melanomas or
cutaneous T-cell lymphomas [0137] localized benign epidermal tumors
such as, for example, keratoderma, epidermal naevi [0138]
chilblains [0139] high blood pressure [0140] syndrome X [0141]
polycystic ovary syndrome (PCOS) [0142] asthma [0143]
osteoarthritis [0144] lupus erythematosus (LE) or inflammatory
rheumatic disorders such as, for example, rheumatoid arthritis
[0145] vasculitis [0146] wasting (cachexia) [0147] gout [0148]
ischemia/reperfusion syndrome [0149] acute respiratory distress
syndrome (ARDS)
[0150] Formulations
[0151] The amount of a compound of the invention necessary to
achieve the desired biological effect depends on a number of
factors, for example the specific compound chosen, the intended
use, the mode of administration and the clinical condition of the
patient. The daily dose is generally in the range from 0.3 mg to
100 mg (typically from 3 mg to 50 mg) per day and per kilogram of
body weight, for example 3-10 mg/kg/day. An intravenous dose may
be, for example, in the range from 0.3 mg to 1.0 mg/kg, which can
suitably be administered as infusion of 10 ng to 100 ng per
kilogram and per minute. Suitable infusion solutions for these
purposes may contain, for example, from 0.1 ng to 10 mg, typically
from 1 ng to 10 mg, per milliliter. Single doses may contain, for
example, from 1 mg to 10 g of the active ingredient. Thus, ampoules
for injections may contain, for example, from 1 mg to 100 mg, and
single-dose formulations which can be administered orally, such as,
for example, tablets or capsules, may contain, for example, from
0.05 to 1000 mg, typically from 0.5 to 600 mg. For the therapy of
the abovementioned conditions, the compounds of formula I may be
used as the compound itself, but they are preferably in the form of
a pharmaceutical composition with an acceptable carrier. The
carrier must, of course, be acceptable in the sense that it is
compatible with the other ingredients of the composition and is not
harmful for the patient's health. The carrier may be a solid or a
liquid or both and is preferably formulated with the compound as a
single dose, for example as a tablet, which may contain from 0.05%
to 95% by weight of the active ingredient. Other pharmaceutically
active substances may likewise be present, including other
compounds of the invention. The pharmaceutical compositions of the
invention can be produced by one of the known pharmaceutical
methods, which essentially consist of mixing the ingredients with
pharmacologically acceptable carriers and/or excipients.
[0152] Pharmaceutical compositions of the invention are those
suitable for oral, rectal, topical, peroral (for example
sublingual) and parenteral (for example subcutaneous,
intramuscular, intradermal or intravenous) administration, although
the most suitable mode of administration depends in each individual
case on the nature and severity of the condition to be treated and
on the nature of the compound of formula I used in each case.
Coated formulations and coated slow-release formulations also
belong within the framework of the invention. Preference is given
to acid- and gastric juice-resistant formulations. Suitable
coatings resistant to gastric juice comprise cellulose acetate
phthalate, polyvinyl acetate phthalate,
hydroxypropylmethylcellulose phthalate and anionic polymers of
methacrylic acid and methyl methacrylate.
[0153] Suitable pharmaceutical preparations for oral administration
may be in the form of separate units such as, for example,
capsules, cachets, suckable tablets or tablets, each of which
contain a defined amount of the compound of formula I; as powders
or granules; as solution or suspension in an aqueous or nonaqueous
liquid; or as an oil-in-water or water-in-oil emulsion. These
compositions may, as already mentioned, be prepared by any suitable
pharmaceutical method which includes a step in which the active
ingredient and the carrier (which may consist of one or more
additional ingredients) are brought into contact. The compositions
are generally produced by uniform and homogeneous mixing of the
active ingredient with a liquid and/or finely divided solid
carrier, after which the product is shaped if necessary. Thus, for
example, a tablet can be produced by compressing or molding a
powder or granules of the compound, where appropriate with one or
more additional ingredients. Compressed tablets can be produced by
tableting the compound in free-flowing form such as, for example, a
powder or granules, where appropriate mixed with a binder, glidant,
inert diluent and/or one or more surface-active/dispersing agent(s)
in a suitable machine. Molded tablets can be produced by molding
the compound, which is in powder form and is moistened with an
inert liquid diluent, in a suitable machine.
[0154] Pharmaceutical compositions which are suitable for peroral
(sublingual) administration comprise suckable tablets which contain
a compound of formula I with a flavoring, normally sucrose and gum
arabic or tragacanth, and pastilles which comprise the compound in
an inert base such as gelatin and glycerol or sucrose and gum
arabic.
[0155] Pharmaceutical compositions suitable for parenteral
administration comprise preferably sterile aqueous preparations of
a compound of formula I, which are preferably isotonic with the
blood of the intended recipient. These preparations are preferably
administered intravenously, although administration may also take
place by subcutaneous, intramuscular or intradermal injection.
These preparations can preferably be produced by mixing the
compound with water and making the resulting solution sterile and
isotonic with blood. Injectable compositions of the invention
generally contain from 0.1 to 5% by weight of the active
compound.
[0156] Pharmaceutical compositions suitable for rectal
administration are preferably in the form of single-dose
suppositories. These can be produced by mixing a compound of the
formula I with one or more conventional solid carriers, for example
cocoa butter, and shaping the resulting mixture.
[0157] Pharmaceutical compositions suitable for topical use on the
skin are preferably in the form of ointment, cream, lotion, paste,
spray, aerosol or oil. Carriers which can be used are petrolatum,
lanolin, polyethylene glycols, alcohols and combinations of two or
more of these substances. The active ingredient is generally
present in a concentration of from 0.1 to 15% by weight of the
composition, for example from 0.5 to 2%.
[0158] Transdermal administration is also possible. Pharmaceutical
compositions suitable for transdermal uses can be in the form of
single patches which are suitable for long-term close contact with
the patient's epidermis. Such patches suitably contain the active
ingredient in an aqueous solution which is buffered where
appropriate, dissolved and/or dispersed in an adhesive or dispersed
in a polymer. A suitable active ingredient concentration is about
1% to 35%, preferably about 3% to 15%. A particular possibility is
for the active ingredient to be released by electrotransport or
iontophoresis as described, for example, in Pharmaceutical
Research, 2(6): 318 (1986).
[0159] The compounds of the formula I with R2 hydrogen are
distinguished by favorable effects on disorders of lipid
metabolism. They beneficially influence the HDL to LDL ratio and
increase in particular the HDL level and are suitable for the
prevention and treatment of dyslipidemias and metabolic syndrome
and their diverse sequelae such as atherosclerosis, coronary heart
disease, heart failure, obesity and diabetes.
[0160] The compounds of the formula I with R1 and R2, which form a
ring system, are distinguished by favorable effects on metabolic
disorders. They beneficially influence lipid and sugar metabolism,
in particular they lower the triglyceride level and are suitable
for the prevention and treatment of type II diabetes and
arteriosclerosis and the diverse sequelae thereof.
[0161] Combinations with Other Medicaments
[0162] The compounds of the invention can be administered alone or
in combination with one or more further pharmacologically active
substances which have, for example, favorable effects on metabolic
disturbances or disorders frequently associated therewith. Examples
of such medicaments are [0163] 1. medicaments which lower blood
glucose, antidiabetics, [0164] 2. active ingredients for the
treatment of dyslipidemias, [0165] 3. antiatherosclerotic
medicaments, [0166] 4. antiobesity agents, [0167] 5.
antiinflammatory active ingredients [0168] 6. active ingredients
for the treatment of malignant tumors [0169] 7. antithrombotic
active ingredients [0170] 8. active ingredients for the treatment
of high blood pressure [0171] 9. active ingredients for the
treatment of heart failure and [0172] 10. active ingredients for
the treatment and/or prevention of complications caused by diabetes
or associated with diabetes.
[0173] They can be combined with the compounds of the invention of
the formula I in particular for a synergistic improvement in the
effect. Administration of the active ingredient combination can
take place either by separate administration of the active
ingredients to the patient or in the form of combination products
in which a plurality of active ingredients are present in one
pharmaceutical preparation.
[0174] Examples which may be mentioned are:
[0175] Antidiabetics
[0176] Suitable antidiabetics are disclosed for example in the Rote
Liste 2001, chapter 12 or in the USP Dictionary of USAN and
International Drug Names, US Pharmacopeia, Rockville 2003.
Antidiabetics include all insulins and insulin derivatives such as,
for example, Lantus.RTM. (see www.lantus.com) or Apidra, and other
fast-acting insulins (see U.S. Pat. No. 6,221,633), GLP-1 receptor
modulators as described in WO 01/04146 or else, for example, those
disclosed in WO 98/08871 of Novo Nordisk A/S.
[0177] The orally effective hypoglycemic active ingredients
include, preferably, the sulfonylureas which act on the
ATP-dependent potassium channel of the beta cells (e.g. disclosed
in WO 97/26265 and WO 99/03861), biguanides, meglitinides, glucagon
antagonists, oral GLP-1 agonists, DPP-IV inhibitors, insulin
sensitizers, e.g. PPAR and PXR modulators and active ingredients
such as, for example, oxadiazolidinediones, thiazolidinediones,
inhibitors of liver enzymes which are involved in stimulating
gluconeogenesis and/or glycogenolysis, modulators of glucose uptake
such as, for example, glucosidase inhibitors, compounds which alter
lipid metabolism and lead to a change in the blood lipid
composition, compounds which reduce food intake or food uptake.
[0178] In one embodiment of the invention, the compounds of the
formula I are administered in combination with insulin.
[0179] In one embodiment of the invention, the compounds of the
formula I are administered in combination with substances which
influence hepatic glucose production such as, for example, glycogen
phosphorylase inhibitors (see: WO 01/94300, WO 02/096864, WO
03/084923, WO 03/084922, WO 03/104188).
[0180] In one embodiment, the compounds of the formula I are
administered in combination with an active ingredient which acts on
the ATP-dependent potassium channel of the beta cells, such as, for
example, sulfonylureas (e.g. tolbutamide, glibenclamide, glipizide,
glimepiride) or glinides (e.g. repaglinide).
[0181] In one embodiment, the compounds of the formula I are
administered in combination with a biguanide such as, for example,
metformin.
[0182] In one embodiment, the compounds of the formula I are
administered in combination with a PPARgamma agonist or
thiazolidinedione such as, for example, ciglitazone, pioglitazone,
rosiglitazone or the compounds disclosed in WO 97/41097 of Dr.
Reddy's Research Foundation, in particular
5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinylmethoxy]phenyl]methyl]-2-
,4-thiazolidinedione.
[0183] In one embodiment, the compounds of the formula I are
administered in combination with a DPPIV inhibitor as described,
for example, in WO98/19998, WO99/61431, WO99/67278, WO99/67279,
WO01/72290, WO 02/38541, WO03/040174, in particular P 93/01
(1-cyclopentyl-3-methyl-1-oxo-2-pentanammonium chloride), P-31/98,
LAF237
(1-[2-[3-hydroxyadamant-1-ylamino)acetyl]pyrrolidine-2-(S)-carbonitrile),
TS021
((2S,4S)-4-fluoro-1-[[(2-hydroxy-1,1-dimethylethyl)amino]-acetyl]py-
rrolidine-2-carbonitrile monobenzenesulfonate).
[0184] In one embodiment, the compounds of the formula I are
administered in combination with compounds with an inhibitory
effect on SGLT-1 and/or 2, as disclosed directly or indirectly for
example in WO2004/007517, WO2004/052902, WO2004/052903 and
WO2005/121161.
[0185] In one embodiment, the compounds of the formula I are
administered in combination with an .alpha.-glucosidase inhibitor
such as, for example, miglitol or acarbose.
[0186] In one embodiment, the compounds of the formula I are
administered in combination with more than one of the
aforementioned compounds, e.g. in combination with a sulfonylurea
and metformin, a sulfonylurea and acarbose, repaglinide and
metformin, insulin and a sulfonylurea, insulin and metformin,
insulin and troglitazone, insulin and lovastatin, etc.
[0187] Lipid Modulators
[0188] In one embodiment of the invention, the compounds of the
formula I are administered in combination with an HMGCoA reductase
inhibitor such as lovastatin, fluvastatin, pravastatin,
simvastatin, ivastatin, itavastatin, atorvastatin,
rosuvastatin.
[0189] In one embodiment of the invention, the compounds of the
formula I are administered in combination with a bile acid
absorption inhibitor (see, for example, U.S. Pat. No. 6,245,744,
U.S. Pat. No. 6,221,897, U.S. Pat. No. 6,277,831, EP 0683 773, EP
0683 774).
[0190] In one embodiment of the invention, the compounds of the
formula I are administered in combination with a polymeric bile
acid adsorbent such as, for example, cholestyramine,
colesevelam.
[0191] In one embodiment of the invention, the compounds of the
formula I are administered in combination with a cholesterol
resorption inhibitor as described for example in WO 0250027, or
ezetimibe, tiqueside, pamaqueside.
[0192] In one embodiment of the invention, the compounds of the
formula I are administered in combination with an LDL receptor
inducer (see, for example, U.S. Pat. No. 6,342,512).
[0193] In one embodiment, the compounds of the formula I are
administered in combination with bulking agents, preferably
insoluble bulking agents (see, for example, carob/Caromax.RTM.
(Zunft H J; et al., Carob pulp preparation for treatment of
hypercholesterolemia, ADVANCES IN THERAPY (2001 September-October),
18(5), 230-6)). Caromax is a carob-containing product from
Nutrinova, Nutrition Specialties & Food Ingredients GmbH,
Industriepark Hoechst, 65926 Frankfurt/Main). Combination with
Caromax.RTM. is possible in one preparation or by separate
administration of compounds of the formula I and Caromax.RTM..
Caromax.RTM. can in this connection also be administered in the
form of food products such as, for example, in bakery products or
muesli bars.
[0194] In one embodiment of the invention, the compounds of the
formula I are administered in combination with a PPARalpha
agonist.
[0195] In one embodiment of the invention, the compounds of the
formula I are administered in combination with a fibrate such as,
for example, fenofibrate, gemfibrozil, clofibrate, bezafibrate.
[0196] In one embodiment of the invention, the compounds of the
formula I are administered in combination with nicotinic acid or
niacin.
[0197] In one embodiment of the invention, the compounds of the
formula I are administered in combination with a CETP inhibitor,
e.g. CP-529, 414 (torcetrapib).
[0198] In one embodiment of the invention, the compounds of the
formula I are administered in combination with an ACAT
inhibitor.
[0199] In one embodiment of the invention, the compounds of the
formula I are administered in combination with an MTP inhibitor
such as, for example, implitapide.
[0200] In one embodiment of the invention, the compounds of the
formula I are administered in combination with an antioxidant.
[0201] In one embodiment of the invention, the compounds of the
formula I are administered in combination with a lipoprotein lipase
inhibitor.
[0202] In one embodiment of the invention, the compounds of the
formula I are administered in combination with an ATP citrate lyase
inhibitor.
[0203] In one embodiment of the invention, the compounds of the
formula I are administered in combination with a squalene
synthetase inhibitor.
[0204] In one embodiment of the invention, the compounds of the
formula I are administered in combination with a lipoprotein(a)
antagonist.
[0205] In one embodiment of the invention, the compounds of the
formula I are administered in combination with a lipase inhibitor
such as, for example, orlistat.
[0206] In one embodiment, the further active ingredient is
fenfluramine or dexfenfluramine.
[0207] In another embodiment, the further active ingredient is
sibutramine.
[0208] In a further embodiment, the compounds of the formula I are
administered in combination with CART modulators (see
"Cocaine-amphetamine-regulated transcript influences energy
metabolism, anxiety and gastric emptying in mice" Asakawa, A, et
al., M.: Hormone and Metabolic Research (2001), 33(9), 554-558),
NPY antagonists, e.g. naphthalene-1-sulfonic acid
{4-[(4-aminoquinazolin-2-ylamino)methyl]cyclohexylmethyl}amide;
hydrochloride (CGP 71683A)), MC4 agonists (e.g.
1-amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid
[2-(3a-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydropyrazolo[4,3-c]pyridin-
-5-yl)-1-(4-chlorophenyl)-2-oxoethyl]amide; (WO 01/91752)), orexin
antagonists (e.g.
1-(2-methylbenzoxazol-6-yl)-3-[1,5]naphthyridin-4-ylurea;
hydrochloride (SB-334867-A)), H3 agonists
(3-cyclohexyl-1-(4,4-dimethyl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-y-
l)propan-1-one oxalic acid salt (WO 00/63208)); TNF agonists, CRF
antagonists (e.g.
[2-methyl-9-(2,4,6-trimethylphenyl)-9H-1,3,9-triazafluoren-4-yl]dipropyla-
mine (WO 00/66585)), CRF BP antagonists (e.g. urocortin), urocortin
agonists, .beta.3 agonists (e.g.
1-(4-chloro-3-methanesulfonylmethylphenyl)-2-[2-(2,3-dimethyl-1H-indol-6--
yloxy)ethylamino]ethanol; hydrochloride (WO 01/83451)), MSH
(melanocyte-stimulating hormone) agonists, CCK-A agonists (e.g.
{2-[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)thiazol-2-ylcar-
bamoyl]-5,7-dimethylindol-1-yl}acetic acid trifluoroacetic acid
salt (WO 99/15525)), serotonin reuptake inhibitors (e.g.
dexfenfluramine), mixed serotoninergic and noradrenergic compounds
(e.g. WO 00/71549), 5HT agonists e.g.
1-(3-ethylbenzofuran-7-yl)piperazine oxalic acid salt (WO
01/09111), bombesin agonists, galanin antagonists, growth hormone
(e.g. human growth hormone), growth hormone-releasing compounds
(6-benzyloxy-1-(2-diisopropylaminoethylcarbamoyl)-3,4-dihydro-1H-isoquino-
line-2-carboxylic acid tertiary butyl ester (WO 01/85695)), TRH
agonists (see, for example, EP 0 462 884), uncoupling protein 2 or
3 modulators, leptin agonists (see, for example, Lee, Daniel W.;
Leinung, Matthew C.; Rozhayskaya-Arena, Marina; Grasso, Patricia.
Leptin agonists as a potential approach to the treatment of
obesity. Drugs of the Future (2001), 26(9), 873-881), DA agonists
(bromocriptine, Doprexin), lipase/amylase inhibitors (e.g. WO
00/40569), PPAR modulators (e.g. WO 00/78312), RXR modulators or
TR-13 agonists.
[0209] In another embodiment, the further active ingredient is a
cannabinoid receptor 1 antagonist (such as, for example,
rimonabant, SR147778 or those as are described in, for example, EP
0656354, WO 00/15609, WO 02/076949, WO2005080345, WO2005080328,
WO2005/080343, WO2005/075450, WO2005/080357, WO2001/70700,
WO2003/026647-48, WO2003/02776, WO2003/040107, WO2003/007887,
WO2003/027069, U.S. Pat. No. 6,509,367, WO2001/32663,
WO2003/086288, WO2003/087037, WO2004/048317, WO2004/058145,
WO2003/084930, WO2003/084943, WO2004/058744, WO2004/013120,
WO2004/029204, WO2004/035566, WO2004/058249, WO2004/058255,
WO2004/058727, WO2004/069838, US2004/0214837, US2004/0214855,
US2004/0214856, WO2004/096209, WO2004/096763, WO2004/096794,
WO2005/000809, WO2004/099157, US2004/0266845, WO2004/110453,
WO2004/108728, WO2004/000817, WO2005/000820, US2005/0009870,
WO2005/00974, WO2004/111033-34, WO2004/11038-39, WO2005/016286,
WO2005/007111, WO2005/007628, US2005/0054679, WO2005/027837,
WO2005/028456, WO2005/063761-62, WO2005/061509, WO2005/077897).
[0210] In one embodiment of the invention, the further active
ingredient is leptin.
[0211] In one embodiment, the further active ingredient is
dexamphetamine, amphetamine, mazindole or phentermine.
[0212] In one embodiment, the compounds of the formula I are
administered in combination with medicaments having effects on the
coronary circulation and the vascular system, such as, for example,
ACE inhibitors (e.g. ramipril), medicaments which act on the
angiotensin-renine system, calcium antagonists, beta blockers
etc.
[0213] In one embodiment, the compounds of the formula I are
administered in combination with medicaments having an
antiinflammatory effect.
[0214] In one embodiment, the compounds of the formula I are
administered in combination with medicaments which are employed for
cancer therapy and cancer prevention.
[0215] It will be appreciated that every suitable combination of
the compounds of the invention with one or more of the
aforementioned compounds and optionally one or more other
pharmacologically active substances is regarded as falling within
the protection conferred by the present invention.
[0216] The activity of the compounds of the invention of the
formula I was tested in the following enzyme assay systems:
[0217] 1. HSL Inhibition Assay
[0218] 1.1. Preparation of the Partially Purified HSL:
[0219] Isolated rat fat cells are obtained from epididymal adipose
tissue from untreated male rats (Wistar, 220-250 g) by collagenase
treatment in accordance with published methods (e.g. S, Nilsson et
al., Anal. Biochem. 158, 1986, 399-407; G. Fredrikson et al., J.
Biol. Chem. 256, 1981, 6311-6320; H. Tornquist et al., J. Biol.
Chem. 251, 1976, 813-819). The fat cells from 10 rats are washed
three times by flotation with 50 ml of homogenization buffer (25 ml
Tris/HCl, pH 7.4, 0.25 M sucrose, 1 mM ETDA, 1 mM DTT, 10 .mu.g/ml
leupeptin, 10 .mu.g/ml antipain, 20 .mu.g/ml pepstatin) each time
and finally taken up in 10 ml of homogenization buffer. The fat
cells are homogenized in a Teflon-in-glass homogenizer
(Braun-Melsungen) by 10 strokes at 1500 rpm and 15.degree. C. The
homogenate is centrifuged (Sorvall SM24 tubes, 5000 rpm, 10 min,
4.degree. C.). The subnatant between the layer of fat at the top
and the pellet is removed and the centrifugation is repeated. The
subnatant resulting therefrom is centrifuged again (Sorvall SM24
tubes, 20 000 rpm, 45 min, 4.degree. C.). The subnatant is removed,
and 1 g of heparin-Sepharose (Pharmacia-Biotech, CL-6B, washed
5.times. with 25 mM Tris/HCl, pH 7.4, 150 mM NaCl) is added. After
incubation at 4.degree. C. for 60 min (shaking at intervals of 15
min), the mixture is centrifuged (Sorvall SM24 tubes, 3000 rpm, 10
min, 4.degree. C.). The supernatant is adjusted to pH 5.2 by adding
glacial acetic acid and is incubated at 4.degree. C. for 30 min.
The precipitates are collected by centrifugation (Sorvall SS34, 12
000 rpm, 10 min, 4.degree. C.) and suspended in 2.5 ml of 20 mM
Tris/HCl, pH 7.0, 1 mM EDTA, 65 mM NaCl, 13% sucrose, 1 mM DTT, 10
.mu.g/ml leupeptin/pepstatin/antipain. The suspension is dialyzed
against 25 mM Tris/HCl, pH 7.4, 50% glycerol, 1 mM DTT, 10 .mu.g/ml
leupeptin, pepstatin, antipain at 4.degree. C. overnight and then
loaded onto a hydroxiapatite column (0.1 g per 1 ml of suspension,
equilibrated with 10 mM potassium phosphate, pH 7.0, 30% glycerol,
1 mM DTT). The column is washed with four volumes of equilibration
buffer at a flow rate of 20 to 30 ml/h. The HSL is eluted with one
volume of equilibration buffer containing 0.5 M potassium phosphate
and then dialyzed (see above) and concentrated 5- to 10-fold by
ultrafiltration (Amicon Diaflo PM 10 Filter) at 4.degree. C. The
partially purified HSL can be stored at -70.degree. C. for 4 to 6
weeks.
[0220] 1.2 HSL Activity Assay:
[0221] To prepare the substrate, 25-50 .mu.Ci of
[3H]trioleoylglycerol (in toluene), 6.8 .mu.mol of unlabeled
trioleoylglycerol and 0.6 mg of phospholipids
(phosphatidylcholine/phosphatidylinositol 3:1 w/v) are mixed, dried
with N.sub.2 and then taken up in 2 ml of 0.1 M KPi (pH 7.0) by
ultrasound treatment (Branson 250, microtip, setting 1-2, 2.times.1
min with an interval of 1 min). After addition of 1 ml of KPi and
renewed ultrasound treatment (4.times.30 sec on ice with intervals
of 30 sec), 1 ml of 20% BSA (in KPi) is added (final concentration
of trioleoylglycerol 1.7 mM). For the reaction, 100 .mu.l of
substrate solution are pipetted into 100 .mu.l of HSL solution (HSL
prepared as above, diluted in 20 mM KPi, pH 7.0, 1 mM EDTA, 1 mM
DTT, 0.02% BSA, 20 .mu.g/ml pepstatin, 10 .mu.g/ml leupeptin) and
incubated at 37.degree. C. for 30 min. Addition of 3.25 ml of
methanol/chloroform/heptane (10:9:7) and of 1.05 ml of 0.1 M
K.sub.2CO.sub.3, 0.1 M boric acid (pH 10.5) is followed by thorough
mixing and finally centrifugation (800.times.g, 20 min). After
phase separation, one equivalent of the upper phase (1 ml) is
removed and the radioactivity is determined by liquid scintillation
measurement.
[0222] 1.3 Evaluation of the HSL-Inhibitory Effect:
[0223] Substances are normally tested in four independent mixtures.
The inhibition of the HSL enzymatic activity by a test substance is
determined by comparing with an uninhibited control reaction. The
IC.sub.50 is calculated from an inhibition plot with at least 10
concentrations of the test substance. The GRAPHIT, Elsevier-BIOSOFT
software package is used to analyze the data.
[0224] 2. EL Inhibition Assay:
[0225] 2.1. Preparation of EL
[0226] EL is released as secretory protein in high concentration
into cell culture medium (conditioned medium) by recombinant cell
lines (CHO, HEK293). This is employed as enzyme solution after
concentration.
[0227] 2.2. EL Activity Assay
[0228] The phospholipase-specific substrate
1,2-bis(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-undecan-
oyl)-sn-glycero-3-phosphocholine, (manufacturer Molecular Probes)
is used to characterize the enzymatic activity of endothelial
lipase and the effect of inhibitors. Hydrolysis of the A1 ester
linkage of this phospholipid by the enzyme liberates the
fluorescent dye Bodipy which can be detected after separation by
thin-layer chromatography on an HPTLC plate (silica gel 60, Merck)
or directly in the reaction vessel by measuring the
fluorescence.
[0229] The substrate solution is prepared by taking up 100 .mu.g of
1,2-bis(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-undecan-
oyl)-sn-glycero-3-phospho-choline (manufacturer Molecular Probes),
2.4 mg of tripalmitin (Sigma) and 7.9 mg of DOP--choline
(1,2-dioleoyl-sn-glycero-3-phosphocholine) in 393 .mu.l of
chloroform and then transferring 157 .mu.l into a fresh reaction
vessel. After evaporation of the solvent, the lipid mixture is
dissolved in 4 ml of 200 mM TRIS-HCl, 150 mM sodium chloride,
pH=7.4, by sonication twice. The subsequent enzymic reaction takes
place at 37.degree. C. for 60 minutes. For this purpose, 45 .mu.l
of the substrate solution are incubated with 1 .mu.l of inhibitor
of appropriate concentration (dissolved in DMSO, pure DMSO solution
is used as control) and 5 .mu.l of enzyme solution (conditioned
medium). Then 3 .mu.l of the assay mixture are loaded onto an HPTLC
plate (silica gel 60, Merck), and the liberated fluorescent dye is
separated for detection with an eluent (diethyl ether:petroleum
benzine:acetic acid [78:22:1]). After evaporation of the eluent,
the plate is read in a fluorescence scanner. An increased
liberation of the fluorescent dye in the uninhibited reaction is to
be observed as a measure of the enzymic activity.
[0230] 2.3. Evaluation of the EL-Inhibitory Effect:
[0231] The enzymatic activity is reduced as a function of the
inhibitor concentration used, and the inhibitor concentration at
which a half-maximum enzymatic activity is observed is called
IC.sub.50.
[0232] 2.4. Further EL Inhibition Assay:
[0233] The phospholipase-specific substrate
1,2-bis(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-undecan-
oyl)-sn-glycero-3-phosphocholine, (manufacturer Molecular Probes)
is used to characterize the enzymatic activity of endothelial
lipase and the effect of inhibitors. Hydrolysis of the A1 ester
linkage of this phospholipid by the enzyme liberates the
fluorescent dye Bodipy which can be detected after separation by
thin-layer chromatography on an HPTLC plate (silica gel 60, Merck)
or directly in the reaction vessel by measuring the
fluorescence.
[0234] The substrate solution is prepared by dissolving 100 pg of
1,2-bis(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-undecan-
oyl)-sn-glycero-3-phospho-choline (manufacturer Molecular Probes)
in 100 .mu.l of DMSO and taking up in 2.4 mg of tripalmitin (Sigma)
in 393 .mu.l of chloroform which comprises 20 mg/ml DOP--choline
(1,2-dioleoyl-sn-glycero-3-phosphocholine). 39.3 .mu.l of this
lipid mixture are transferred into a fresh reaction vessel, and the
solvent is evaporated off. The lipid mixture is dissolved in 4 ml
of 200 mM TRIS-HCl, 150 mM sodium chloride, pH=7.4, by sonication
twice. The subsequent enzymic reaction takes place at 37.degree. C.
for 90 minutes. For this purpose, 20 .mu.l of the substrate
solution are incubated with 2 .mu.l of inhibitor of appropriate
concentration (dissolved in 10% DMSO, using 10% strength DMSO
solution for control) and 2 .mu.l of enzyme solution (conditioned
medium). The 4 .mu.l of the assay mixture are loaded onto an HPTLC
plate (silica gel 60, Merck), and the liberated fluorescent dye is
separated for detection with an eluent (diethyl ether:petroleum
benzine:acetic acid [78:22:1]). After evaporation of the eluent,
the plate is read in a fluorescence scanner. An increased
liberation of the fluorescent dye in the uninhibited reaction is to
be observed as a measure of the enzymic activity.
[0235] In this assay, the compounds of the examples showed the
following IC.sub.50 values:
TABLE-US-00001 IC.sub.50 Example [.mu.M] EL 1 0.05 2 0.01 3 0.069 4
0.39 5 0.01 9 0.011 11 0.354 13 0.0005 14 0.18 15 0.23 16 0.18 17
0.061 18 0.48 19 0.083 20 0.09
Preparation Processes
[0236] The compounds of the invention of the general formula I are
prepared by methods known per se, e.g. by acylation of substituted
or unsubstituted azolopyridin-2-one derivatives II with carbamoyl
chlorides III (method A), or in two stages by reacting
azolopyridin-2-one derivatives II with phosgene or equivalents such
as trichloromethyl chlorocarbonate, ditrichloromethyl carbonate or
4-nitrophenyl chloroformate and further reaction of the resulting
azolopyridin-2-onecarboxylic acid derivative with amines IV (method
B). For compounds in which R2 is hydrogen, the azolopyridin-2-one
derivatives II can also be reacted with the appropriate isocyanates
V R1-N.dbd.C.dbd.O.
##STR00004##
[0237] Since acids are usually liberated in these reactions, it is
advisable to add bases such as pyridine, triethylamine, sodium
hydroxide solution or alkali metal carbonates for expedition. The
reactions can be carried out in wide temperature ranges. It has
usually proved to be advantageous to operate at from 0.degree. C.
to the boiling point of the solvent used. Examples of solvents
employed are methylene chloride, THF, DMF, toluene, ethyl acetate,
n-heptane, dioxane, diethyl ether or pyridine. If anhydrous
conditions are used, strong bases such as lithium hydride, sodium
hydride or potassium tert-butoxide in aprotic solvents such as THF
or DMF have also proved suitable.
[0238] The azolopyridin-2-one derivatives or corresponding
aza-substituted derivatives employed as starting compounds II are
commercially available or can be prepared by processes known from
the literature (e.g. C. Flouzat, Y. Bresson, A. Mattio, J. Bonnet,
G. Guillaumet J. Med. Chem. 1993, 36, 497-503; F. Mutterer, C. D.
Weis, J. Het. Chem. 1976, 13, 1103-1104; K. Bowden, G. Crank, W. J.
Ross, J. Chem. Soc. 1968, 172-185).
[0239] The examples detailed below serve to illustrate the
invention without, however, restricting it.
EXAMPLES
Example 1
2-Oxo-oxazolo[4,5-b]pyridin-3-(2-methylbenzyl)carboxamide
[0240] 100 mg (0.735 mmol) of 3H-oxazolo[4,5-b]pyridin-2-one were
dissolved in 5 ml of THF. Addition of 129.8 mg (0.882 mmol) of
2-methylbenzyl isocyanate was followed by stirring at 70.degree. C.
for 5 h, addition once again of the same amount of 2-methylbenzyl
isocyanate, and stirring 70.degree. C. for 5 h. The reaction
mixture was concentrated and purified by preparative HPLC (PR18,
acetonitrile/water 0.1% TFA). Yield: 55 mg (26%), M+H+: 284.1.
Example 2
6-Bromo-2-oxo-oxazolo[4,5-b]pyridine-3-(2-methylbenzyl)carboxamide
[0241] 100 mg (0.465 mmol) of
6-bromo-3H-oxazolo[4,5-b]pyridin-2-one were reacted in analogy to
Example 1 with 102.7 mg (0.698 mmol) of 2-methylbenzyl isocyanate
in THF at 70.degree. C. Yield: 13 mg (8%), M+H+: 362.05.
Example 3
2-Oxo-oxazolo[4,5-b]pyridine-3-hexylcarboxamide
[0242] 100 mg (0.74 mmol) of 3H-oxazolo[4,5-b]pyridin-2-one were
reacted in analogy to Example 1 with 102.8 mg (0.809 mmol) of
1-isocyanatohexane in dioxane at 80.degree. C. Yield: 77 mg (40%),
M+H+: 264.12.
Example 4
2-Oxo-oxazolo[4,5-b]pyridine-3-(3-methylbenzyl)carboxamide
[0243] 200 mg (1.47 mmol) of 3H-oxazolo[4,5-b]pyridin-2-one were
reacted in analogy to Example 1 with 324.3 mg (2.2 mmol) of
1-isocyanatomethyl-3-methylbenzene in dioxane at 80.degree. C.
Yield: 322 mg (77%), M+H+: 284.1.
Example 5
2-Oxo-oxazolo[4,5-b]pyridine-3-(3,4-dimethylbenzyl)carboxamide
[0244] 200 mg (1.47 mmol) of 3H-oxazolo[4,5-b]pyridin-2-one were
reacted in analogy to Example 1 with 284 mg (1.76 mmol) of
3,4-dimethylbenzyl isocyanate in dioxane at 80.degree. C. Yield:
110 mg (25%), M+H+: 298.1.
Example 6
3-(4-Methylpiperidine-1-carbonyl)-3H-oxazolo[4,5-b]pyridin-2-one
[0245] 100 mg (0.735 mmol) of 3H-oxazolo[4,5-b]pyridin-2-one, 235
mg (1.45 mmol) of 4-methylpiperidine-1-carbonyl chloride and 101
.mu.l (2.18 mmol) of triethylamine were stirred in 5 ml of pyridine
at room temperature for 3 h. The reaction mixture was concentrated,
and the residue was dissolved in water and extracted with ethyl
acetate. The organic phase was concentrated and purified by
preparative HPLC (PR18, acetonitrile/water 0.1% TFA). Yield: 6 mg
(3%), M+H+: 262.12.
Example 7
6-Bromo-3-(4-methylpiperidine-1-carbonyl)-3H-oxazolo[4,5-b]pyridin-2-one
[0246] 100 mg (0.46 mmol) of 6-bromo-3H-oxazolo[4,5-b]pyridin-2-one
were reacted in analogy to Example 6 with 150 mg (0.93 mmol) of
4-methylpiperidin-1-carbonyl chloride. Yield: 78 mg (50%), M+H+:
340.09.
Example 8
2-Oxo-oxazolo[4,5-b]pyridine-3-phenethylcarboxamide
[0247] 300 mg (2.2 mmol) of 3H-oxazolo[4,5-b]pyridin-2-one were
reacted in analogy to Example 1 with 389 mg (2.6 mmol) of
(2-isocyanatoethyl)benzene in dioxane at 80.degree. C. Yield: 436
mg (70%), M+H+: 284.07.
Example 9
2-Oxo-oxazolo[4,5-b]pyridine-3-heptylcarboxamide
[0248] 200 mg (1.47 mmol) of 3H-oxazolo[4,5-b]pyridin-2-one were
reacted in analogy to Example 1 with 207 mg (1.47 mmol) of
1-isocyanatoheptane in dioxane at 80.degree. C. Yield: 416 mg
(10%), M+H+: 278.15.
Example 10
2-Oxo-oxazolo[4,5-b]pyridine-3-benzylcarboxamide
[0249] 100 mg (0.735 mmol) of 3H-oxazolo[4,5-b]pyridin-2-one were
reacted in analogy to Example 1 with 117 mg (0.88 mmol) of
isocyanatomethylbenzene in dioxane at 80.degree. C. Yield: 30 mg
(15%), M+H+: 270.11.
Example 11
2-Oxo-oxazolo[4,5-b]pyridine-3-butylcarboxamide
[0250] 300 mg (2.2 mmol) of 3H-oxazolo[4,5-b]pyridin-2-one were
reacted in analogy to Example 1 with 262 mg (2.6 mmol) of
1-isocyanatobutane in dioxane at 80.degree. C. Yield: 91 mg (18%),
M+H+: 236.15.
Example 12
6-Bromo-2-oxo-oxazolo[4,5-b]pyridine-3-benzylcarboxamide
[0251] 100 mg (0.46 mmol) of 6-bromo-3H-oxazolo[4,5-b]pyridin-2-one
were reacted in analogy to Example 1 with 74.3 mg (0.56 mmol) of
isocyanatomethylbenzene in dioxane at 80.degree. C. Yield: 10 mg
(6%), M+H+: 348.10.
Example 13
2-oxo-oxazolo[4,5-b]pyridin-3-(1,2,3,4-tetrahydronaphthalen-1-yl)carboxami-
de
[0252] 100 mg (0.735 mmol) of 3H-oxazolo[4,5-b]pyridin-2-one were
reacted in analogy to Example 1 with 127 mg (0.735 mmol) of
1-isocyanato-1,2,3,4-tetrahydronaphthalene in dioxane at 80.degree.
C. Yield: 29 mg (13%), M+H+: 310.10.
Example 14
2-Oxo-oxazolo[4,5-b]pyridine-3-(R)-indan-1-yl)carboxamide
[0253] 100 mg (0.735 mmol) of 3H-oxazolo[4,5-b]pyridin-2-one were
reacted in analogy to Example 1 with 140 mg (0.88 mmol) of
(R)-1-isocyanatoindane in dioxane at 60.degree. C. Yield: 22 mg
(10%), M+H+: 296.14.
Example 15
2-Oxo-oxazolo[4,5-b]pyridine-3-(S)-indan-1-yl)carboxamide
[0254] 100 mg (0.735 mmol) of 3H-oxazolo[4,5-b]pyridin-2-one were
reacted in analogy to Example 1 with 140 mg (0.88 mmol) of
(S)-1-isocyanatoindane in dioxane at 60.degree. C. Yield: 8 mg
(40%), M+H+: 296.14.
Example 16
2-Oxo-oxazolo[4,5-b]pyridin-3-dodecylcarboxamide
[0255] 100 mg (0.735 mmol) of 3H-oxazolo[4,5-b]pyridin-2-one were
reacted in analogy to Example 1 with 155.3 mg (0.735 mmol) of
1-isocyanatododecane in dioxane at 80.degree. C. Yield: 33 mg
(13%), M+H+: 348.25.
Example 17
5-Methyl-2-oxo-oxazolo[4,5-b]pyridine-3-(2-methylbenzyl)carboxamide
[0256] 150 mg (1 mmol) of 5-methyl-3H-oxazolo[4,5-b]pyridin-2-one
were reacted in analogy to Example 1 with 176 mg (1.2 mmol) of
1-isocyanatomethyl-2-methylbenzene and 100 .mu.l of pyridine in
toluene at 115.degree. C. Yield: 3 mg (1%), M+H+: 298.13.
Example 18
2-Oxo-oxazolo[4,5-b]pyridine-3-cyclohexylmethylcarboxamide
[0257] 100 mg (0.735 mmol) of 3H-oxazolo[4,5-b]pyridin-2-one were
reacted in analogy to Example 1 with 102 mg (0.735 mmol) of
isocyanatomethylcyclohexane in dioxane at 80.degree. C. Yield: 43
mg (21%), M+H+: 276.13.
Example 19
2-Oxo-oxazolo[4,5-b]pyridine-3-octylcarboxamide
[0258] 200 mg (1.47 mmol) of 3H-oxazolo[4,5-b]pyridin-2-one were
reacted in analogy to Example 1 with 273.7 mg (1.76 mmol) of
1-isocyanatooctane in dioxane at 80.degree. C. Yield: 40 mg (9%),
M+H+: 292.10.
Example 20
2-Oxo-oxazolo[4,5-b]pyridine-3-nonylcarboxamide
[0259] 200 mg (1.47 mmol) of 3H-oxazolo[4,5-b]pyridin-2-one were
reacted in analogy to Example 1 with 298.4 mg (1.76 mmol) of
1-isocyanatononane in dioxane at 80.degree. C. Yield: 40 mg (9%),
M+H+: 306.20.
* * * * *
References